Business
MustGrow Reports Successful Banana Field Trials in Colombia; Program Transitions to Sumitomo Corporation
Field data confirmed reduced incidence and severity of Fusarium wilt TR4 symptoms in banana p...
About this update from Mustgrow Biologics Corp.
[{"type":"text","content":"MustGrow Reports Successful Banana Field Trials in Colombia; Program Transitions to Sumitomo CorporationField data confirmed reduced incidence and severity of Fusarium wilt TR4 symptoms in banana plants after application of MustGrow's product. No damage or phytotoxic effects on banana plants, even at higher dose rates.Colombia banana program transitions to Sumitomo Corporation.Sumitomo Corporation to drive project and field development, as well as regulatory work necessary for commercialization.Saskatoon, Saskatchewan--(Newsfile Corp. - November 10, 2021) - MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (\"MustGrow\") is pleased to announce the success of its initial field trial program in Colombia. Field testing confirmed the efficacy of MustGrow's mustard plant-derived biopesticide in treating the disease Fusarium wilt TR4 - a unique feat MustGrow believes no other agri-science team has achieved. Fusarium wilt TR4 (often referred to as the Panama Disease) is a devastating pathogen ravaging the $25 billion global banana industry. Positive Dose Response in FieldAfter application of MustGrow's mustard-based biopesticide, TerraMG, field data confirmed reduced incidence and severity of Fusarium wilt TR4 symptoms in banana plants after 21 days. Importantly, even at higher application rates there was no damage or phytotoxic effects to the banana plants, allowing MustGrow to explore treating the banana plants directly, in addition to soil applications.Data confirmed a reduced concentration in colony-forming units (CFU*) per gram of soil 21 days after application. There is a strong correlation between the level of CFU in soil and disease severity.* A colony-forming unit (CFU) is a microbiology unit used to estimate the number of viable (the ability to multiply) bacteria or fungal cells in a sample.Sumitomo Corporation (TYO: 8053) (OTC: SSUMY) will now drive field development work including dose rates, application frequency, application methods, and the regulatory work necessary for commercialization. On August 4, 2021, MustGrow announced an Exclusive Evaluation and Option Agreement with Sumitomo Corporation to evaluate MustGrow's technology for the purpose of determining efficacy and commercial potential. Sumitomo Corporation has exclusive option rights to MustGrow's technology for preplant soil fumigation, bioherbicide...